It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

Genome editing is an exciting but still nascent ... Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology. Since that discovery, a flurry of gene ...

Mutations of CCR5 have been linked to improved outcome to HIV infection. Here the authors use CRISPR-Cas9 genome editing of CCR5 in mobilized hematopoietic stem progenitor cells and show ...

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect early embryonic ...

Gen Biomanufacturing InitiativesDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...